2,3-二氯苯乙酮 | 56041-57-7

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,3-二氯苯乙酮
• 中文别名: 2',3'-二氯苯乙酮
• 英文名称: 2',3'-dichloroacetophenone
• 英文别名: 2,3-Dichloracetophenon；1-(2,3-dichlorophenyl)ethanone；1-(2,3-dichlorophenyl)-1-ethanone
• CAS: 56041-57-7
• 化学式: C₈H₆Cl₂O
• mdl: MFCD00052988
• 分子量: 189.041
• InChiKey: KMABBMYSEVZARZ-UHFFFAOYSA-N

物化性质

• 熔点：
  125-127 °C
• 沸点：
  67 °C
• 密度：
  1.293
• 闪点：
  106-108°C/2mm
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会发生分解，目前尚未发现已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2914700090
• 安全说明：
  S26,S36/37/39,S37/39
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保持贮藏器密封，并将其存放在阴凉、干燥处。确保工作间有良好的通风或排气装置。

SDS

Name:	1-(2 3-Dichlorophenyl)ethan-1-one 97% Material Safety Data Sheet
Synonym:	2,3-Dichloroacetophenon
CAS:	56041-57-7

Section 1 - Chemical Product MSDS Name:1-(2 3-Dichlorophenyl)ethan-1-one 97% Material Safety Data Sheet
Synonym:2,3-Dichloroacetophenon

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
56041-57-7	1-(2,3-Dichlorophenyl)ethan-1-one	97%	259-954-3

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 56041-57-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 106 - 108 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.293
Molecular Formula: C8H6Cl2O
Molecular Weight: 189

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 56041-57-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2,3-Dichlorophenyl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 56041-57-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 56041-57-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 56041-57-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氯苯乙酮 在 甲醇 、 sodium tetrahydroborate 、 溴 、 sodium 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 1-(2,3-Dichlorophenyl)-2-phenylmethoxyethanol
  参考文献：
  名称：

  [EN] ASYMMETRIC UREAS AND MEDICAL USES THEREOF
  [FR] URÉES ASYMÉTRIQUES ET LEURS UTILISATIONS MÉDICALES

  摘要：

  揭示了一种化合物、组合物和方法，用于预防和/或治疗由胃泌素受体病理生理介导的疾病。这些化合物具有一般公式（I）。

  公开号：

  WO2012113103A1
• 作为产物：
  描述：

  邻二氯苯 在 正丁基锂 、 乙酸酐 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以75%的产率得到2,3-二氯苯乙酮
  参考文献：
  名称：

  Process for the preparation of lamotrigine

  摘要：

  拉莫三嗪，3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪，可能通过用氨处理式（II）的6-(2,3-二氯苯基)-5-氯-3-硫甲基-1,2,4-三嗪来制备##STR1##。还描述了该式（II）化合物的前体及其制备方法。

  公开号：

  US05925755A1

文献信息

• Discovery of novel isoliquiritigenin analogue ISL-17 as a potential anti-gastric cancer agent
  作者：Fengchang Huang、Jin Wang、Yi Xu、Yunfei Zhang、Ning Xu、Liang Yin

  DOI：10.1042/bsr20201199

  日期：2020.6.26

  Isoliquiritigenin (ISL), a natural product isolated from licorice root, exhibits anti-gastric cancer effects. However, applications of ISL are still limited in clinical practice due to its poor bioavailability. To discovery of more effective anti-gastric cancer agents based on ISL, aldol condensation reaction was applied to synthesize the ISL analogues. MTS assay was used to evaluate the inhibitory activities of ISL analogues against SGC-7901, BGC-823 and GES-1 cells in vitro. Cell cycle distribution, apoptosis and reactive oxygen species (ROS) generation were detected by flow cytometry. Western blot assay was used to analyze the expression levels of related proteins. The drug-likeness and pharmacokinetic properties were predicted with Osiris property explorer and PreADMET server. As a result, 18 new ISL analogues (ISL-1 to ISL-18) were synthesized. Among these analogues, ISL-17 showed the strongest inhibitory activities against SGC-7901 and BGC-823 cells, and could induce G2/M cell cycle arrest and apoptosis in these two cell lines. Treatment with ISL-17 resulted in increased ROS production and elevated autophagy levels in SGC-7901 cells. The PI3K/AKT/mTOR signaling pathway was down-regulated after treatment with ISL-17 in SGC-7901 cells. The results of drug-likeness and pharmacokinetic prediction indicated that all the ISL analogues complied with Lipinski's rule of five and Veber rule and had a favorable ADME character. Overall, our results attest that ISL-17 holds promise as a candidate agent against gastric cancer.

  摘要 Isoliquiritigenin (ISL) 是一种从甘草根中分离出来的天然产物，具有抗胃癌作用。然而，由于 ISL 的生物利用度较低，其在临床上的应用仍然有限。为了发现基于 ISL 的更有效的抗胃癌药物，研究人员采用醛醇缩合反应合成了 ISL 类似物。采用 MTS 法评估 ISL 类似物对 SGC-7901、BGC-823 和 GES-1 细胞的体外抑制活性。流式细胞仪检测细胞周期分布、细胞凋亡和活性氧（ROS）生成。用 Western 印迹法分析了相关蛋白的表达水平。利用 Osiris Property explorer 和 PreADMET 服务器预测了药物相似性和药代动力学特性。结果合成了 18 种新的 ISL 类似物（ISL-1 至 ISL-18）。在这些类似物中，ISL-17 对 SGC-7901 和 BGC-823 细胞具有最强的抑制活性，能诱导这两种细胞系的 G2/M 细胞周期停滞和细胞凋亡。用 ISL-17 处理 SGC-7901 细胞会导致 ROS 生成增加和自噬水平升高。用 ISL-17 处理 SGC-7901 细胞后，PI3K/AKT/mTOR 信号通路下调。药物相似性和药代动力学预测结果表明，所有 ISL 类似物都符合利宾斯基五法则和维伯法则，具有良好的 ADME 特性。总之，我们的研究结果证明 ISL-17 有希望成为一种抗胃癌的候选药物。
• [EN] SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A] PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE SUBSTITUÉS POUVANT ÊTRE UTILISÉS POUR LE TRAITEMENT DE (ENTRE AUTRES) LA MALADIE D'ALZHEIMER
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2013171712A1

  公开（公告）日：2013-11-21

  The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及新颖的Formula (I)中的取代3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物，其中R1、R2、R3、R4、R5、Z和X的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新颖化合物的方法，包括将这些化合物作为活性成分的药物组合物，以及将这些化合物用作药物的用途。
• Synthesis and SAR of 4-Aryl-2-hydroxy-4-oxobut-2-enoic Acids and Esters and 2-Amino-4-aryl-4-oxobut-2-enoic Acids and Esters:  Potent Inhibitors of Kynurenine-3-hydroxylase as Potential Neuroprotective Agents
  作者：Martin J. Drysdale、S. Lucy Hind、Marilyn Jansen、John F. Reinhard

  DOI：10.1021/jm990396t

  日期：2000.1.1

  The synthesis and structure-activity relationship of a series of 4-aryl-2-hydroxy-4-oxobut-2-enoic acids and esters and 2-amino-4-aryl-4-oxobut-2-enoic acids and esters as potent inhibitors of kynurenine-3-hydroxylase are described. These compounds are the most potent inhibitors of the kynurenine-3-hydroxylase enzyme so far disclosed. Additionally methyl 4-(3-chlorophenyl)-2-hydroxy-4-oxobut-2-enoate

  一系列有效的4-芳基-2-羟基-2-羟基-4-氧代丁-2-烯酸和酯与2-氨基-4-芳基-4-氧代丁-2-烯酸和酯的合成及其构效关系描述了犬尿氨酸-3-羟化酶的抑制剂。这些化合物是迄今公开的最有效的犬尿氨酸-3-羟化酶的抑制剂。此外，4-（3-氯苯基）-2-羟基-4-氧代丁-2-烯酸甲酯（2d），4-（3-氯苯基）-2-羟基-4-氧代丁-2-烯酸（3d），甲基4-（3-氟苯基）-2-羟基-4-氧丁-2-烯酸酯（2f）和4-（3-氟苯基）-2-羟基-4-氧丁-2-烯酸（3f）干扰素-γ诱导的人外周血单核细胞衍生巨噬细胞原代培养物中喹啉酸的合成。
• Multitarget Compounds Active at a PPAR and Cannabinoid Receptor
  申请人：Desreumaux Pierre

  公开号：US20110039808A1

  公开（公告）日：2011-02-17

  There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group.

  需要具有至少一种PPAR和大麻受体活性的药物化合物。因此提供了这样的化合物，其中该化合物包括：由包含一个五元环与一个六元环或一个六元环与一个六元环融合的融合双环环的基团连接在一起的PPAR药效团和大麻药效团；其中大麻药效团包括融合双环环；而PPAR药效团包括水杨酸、烷氧基苯乙酸或烷氧基苯乙酸官能团；PPAR药效团通过包含胺基或酰胺官能团的连接物连接到大麻药效团的双环环上。
• [EN] 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS<br/>[FR] COMPOSES 1H-PYRAZOLE 3,4-DISUBSTITUES ET LEUR UTILISATION EN TANT QUE KINASES DEPENDANT DES CYCLINES (CDK) ET MODULATEURS DE LA GLYCOGENE SYNTHASE KINASE-3 (GSK-3)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005012256A1

  公开（公告）日：2005-02-10

  The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. Formula (0). In formula (0): X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).

  该发明提供了以下式（0）的化合物或其盐或互变异构体或N-氧化物或其溶剂合物，用于预防或治疗由细胞周期依赖性激酶和糖原合成酶-3介导的癌症等疾病状态和病症。在式（0）中：X是一个基团R1-A-NR4-或一个5-或6-成员的碳环或杂环；A是一个键，S02，C=O，NRg（C=O）或O（C=O），其中Rg是氢或C1-4烃基，可以选择性地被羟基或C1-4烷氧基取代；Y是一个键或一个由1、2或3个碳原子组成的烷基链；R1是氢；一个具有3到12个环成员的碳环或杂环基团；或一个C1-8烃基，可以选择性地被卤素（如氟）、羟基、C1-4烷氧基、氨基、单或双C1-4烃基氨基以及具有3到12个环成员的碳环或杂环基团取代，其中烃基的1或2个碳原子可以选择性地被从0、S、NH、SO、S02中选择的原子或基团所取代；R2是氢；卤素；C1-4烷氧基（如甲氧基）；或一个C1-4烃基，可以选择性地被卤素（如氟）、羟基或C1-4烷氧基（如甲氧基）取代；R3从氢和具有3到12个环成员的碳环或杂环基团中选择；R4是氢或一个C1-4烃基，可以选择性地被卤素（如氟）、羟基或C1-4烷氧基（如甲氧基）取代。